Alkem, INE540L01014

Alkem Laboratories stock: Q2 revenue rises as net profit falls

Published on 11/17/2026 at 03:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alkem Laboratories stock faces a mixed Q2 picture as revenue rose 13.8%. Higher expenses drove consolidated net profit lower in the September quarter.

Mixed quarterly performance

  • Revenue from operations increased to INR 45.52 billion in Q2 FY27 from INR 40.01 billion a year earlier.
  • Consolidated net profit declined to INR 6.67 billion from INR 7.79 billion as expenses rose.
  • India revenue grew 9.5 percent, while international revenue increased 22.3 percent.
Alkem, INE540L01014, Illustration mit AI erstellt.

Alkem Laboratories reported on Thursday, November 12, that consolidated revenue from operations rose 13.8 percent year over year to INR 45.52 billion in the quarter ended September 30, 2026. Consolidated net profit fell 14.37 percent to INR 6.67 billion from INR 7.79 billion a year earlier, according to Business Standard.

Revenue growth meets cost pressure

The result covers Alkem's second quarter of fiscal 2027. Total expenses increased to INR 37.22 billion from INR 32.09 billion in the year-earlier quarter, weighing on the bottom line despite stronger sales.

India business revenue rose 9.5 percent year over year to INR 30.28 billion. International revenue increased 22.3 percent to INR 14.54 billion, giving overseas operations a larger contribution to the quarter's growth.

Domestic and overseas focus

Managing Director Sandeep Singh said the India business benefited from execution across acute and chronic portfolios. He also cited steady international progress despite pricing pressure in the United States, with volume growth providing support.

Alkem said it expanded its MedTech presence through the addition of Occlutech during the quarter. Management also identified improving execution and operating performance at Enzene as a priority, keeping the newer businesses central to the company's medium-term development.

Pharmaceutical platform and peers

Alkem Laboratories develops, manufactures and sells pharmaceutical and nutraceutical products in India, the United States and international markets. Its portfolio includes branded and trade generics, complex generics, biosimilars, active pharmaceutical ingredients and consumer wellness products. The company is based in Mumbai, India.

Simply Wall St lists Glenmark Pharmaceuticals, Abbott India and Gland Pharma among Alkem's competitors. Alkem combines domestic branded medicines with United States generics and international pharmaceutical sales, while those peers represent comparable Indian healthcare businesses with different portfolio mixes.

Alkem Laboratories at a glance

  • Company: Alkem Laboratories Limited
  • ISIN: INE540L01014
  • Ticker: ALKEM
  • Sector: Pharmaceuticals and biotechnology
  • Headquarters: Mumbai, India

Indian equities trade in the market environment tracked by the BSE Sensex.

Find More news and analyses on Alkem Laboratories stock.

Disclaimer...
en | INE540L01014 | ALKEM | boerse | 70524079 | bgmi